Combination Diet |
|
|
Clinical Trial: Phase 1-2a Dose-Ranging Study of TLK286 in Combination with Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer
This study is no longer recruiting patients.
|
Purpose
The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every three weeks in combination with docetaxel (Taxotere) in the treatment of patients with non-small cell lung cancer that is resistant to platinum-based chemotherapy.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Drug: TLK286 in combination with docetaxel | Phase I Phase II |
MedlinePlus related topics: Cancer; Lung Cancer
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title: Phase 1-2a Dose-Ranging Study of TLK286 in Combination with Docetaxel (Taxotere) in Platinum-Resistant Non-Small Cell Lung Cancer
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion criteria include:
- Histologically confirmed non-small cell bronchogenic carcinoma, including squamous cell carcinoma, undifferentiated carcinoma, adenocarcinoma, mixed (adenocarcinoma with squamous cell carcinoma), bronchoalveolar carcinoma, or large cell carcinoma
- Stage IV or Stage IIIB
- Progressed during or after first-line therapies with platinum-containing regimens in the advanced or metastatic treatment regimen
- At least 18 years of age
- Good performance status (ECOG 0 to 1)
- Adequate liver, renal, and bone marrow function
Exclusion criteria include:
- Pregnant or lactating women
- Treatment with more than one cytotoxic therapy
- Prior radiation to the whole pelvis
- Unstable medical conditions such as uncontrolled cardiac arrhythmia
- Patients with known history of severe hypersensitivity reactions to docetaxel or other drugs formulated with polysorbate 80
Location Information
California
Cancer Institute Medical Group, Los Angeles, California, 90025, United States
UCLA Medical Center, Los Angeles, California, 90095, United States
Indiana
Indiana University Cancer Center, Indianapolis, Indiana, 46202, United States
Texas
M.D. Anderson Cancer Center, Houston, Texas, 77030, United States
More Information
Record last reviewed: October 2003
Last Updated: October 13, 2004
Record first received: October 18, 2002
ClinicalTrials.gov Identifier: NCT00047801
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Combination Diets: The truth about food combining weight loss. (Chase Freedom)

Not Signed In -

